Steroid Treatment for Acute Liver Failure: Does It Really Help?
"A new study sheds light on the effectiveness of steroid treatment for acute-on-chronic liver failure caused by hepatitis B, revealing surprising results."
Acute-on-chronic liver failure (ACLF) is a severe condition where the liver suddenly deteriorates in individuals with existing chronic liver disease. This can lead to life-threatening complications, and while liver transplantation is often the ideal solution, it isn't always accessible or feasible for every patient.
Researchers have been exploring various medications to manage ACLF, including granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO). Corticosteroids, known for their anti-inflammatory properties, have also been considered as a potential treatment, yet their effectiveness remains a subject of debate.
A recent study published in the journal Hepatology investigated the use of steroid treatment in patients with ACLF caused by hepatitis B. The ten-year cohort study, conducted in a university hospital in East China, aimed to determine whether steroids provide a real benefit or if they might even pose unforeseen risks. Here's what they found.
The Impact of Steroids in Acute Liver Failure
Acute liver failure is a heterogeneous syndrome involving rapid loss of liver function, coagulopathy, and encephalopathy in a person without prior liver disease. Drug-induced acute liver failure is described as the most common cause, with acetaminophen accounting for most cases in that group. Glucocorticoids have been used in liver failure since the 1970s, but their role remains unsettled. A 2022 review reports that, in severe acute exacerbations of chronic hepatitis B, adding low-dose, short-term glucocorticoids to standard treatment reduced progression to liver failure and shortened hospitalization without increasing complications.
A Targeted Steroid Delivery Approach
Liver failure has a poor prognosis, and the source reports that liver transplantation was the only established effective therapy. Researchers previously identified a subgroup of patients with acute liver injury who developed microcirculatory disturbance. They subsequently established and reported transcatheter arterial steroid injection therapy (TASIT), a targeted treatment approach. The source excerpt does not provide its clinical outcomes or establish it as standard therapy.
Steroid Treatment: Not a Miracle Cure for Hepatitis B-Related ACLF?
The study followed 293 patients with hepatitis B-precipitated ACLF from 2007 to 2016. Among them, 162 patients received steroid treatment, while the rest served as a control group. The researchers then compared survival rates, clinical characteristics, and infection occurrences between the two groups.
- No Improvement in Survival: Steroid treatment failed to show a significant increase in survival rates among ACLF patients caused by hepatitis B.
- Increased Infection Risk: Patients treated with steroids experienced a higher frequency of pulmonary and opportunistic infections.
- Key Risk Factors Identified: The study identified age, baseline MELD score >20, and CLIF-C ACLF grade 2-3 as independent risk factors for mortality.
Evidence on Benefits and Risks
A prospective multicenter clinical trial examined methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF); its cited retrospective study found no improvement in transplant-free survival with glucocorticoid treatment. In a separate retrospective case series of pregnant patients with chronic hepatitis B and acute-on-chronic liver failure, pulmonary and opportunistic infections occurred more frequently in the steroid-treated group, with reported P values of 0.003 and less than 0.001, respectively. A plasma-exchange cohort study reported that regional citrate anticoagulation at 48-hour intervals may reduce citrate accumulation complications in patients with acute or acute-on-chronic liver failure. That plasma-exchange finding concerns anticoagulation during treatment, rather than demonstrating a steroid effect.
Benefits May Depend on Disease Severity
A 2016 study evaluation reported that corticosteroids improved prognosis in patients with less severe liver failure but were ineffective once the disease progressed to end-stage liver failure. This finding suggests that any benefit may depend on severity and may not extend to advanced disease. A separate clinical guidance source advises evaluating steroid use according to the cause of liver failure, noting clear indications in alcoholic and autoimmune hepatitis and caution in other forms because of potential adverse effects on mortality. Together, these sources underscore that steroid treatment is not a universal approach to liver failure.
Steroids in Hepatitis B-Related ACLF
Acute-on-chronic liver failure (ACLF) occurs in people with chronic liver disease or cirrhosis and can follow an exacerbation of chronic hepatitis B. The cited study examines corticosteroid treatment in ACLF patients with underlying chronic hepatitis B. Its supplied source excerpt identifies the population and topic but does not provide results or a comparison group’s outcomes. Therefore, the available information does not support a conclusion about whether corticosteroids outperform other treatment approaches.
The Bottom Line: Rethinking Steroids for ACLF
This research suggests that steroid treatment may not be a beneficial strategy for ACLF patients with hepatitis B and could even increase the risk of infections. The study emphasizes the importance of identifying key risk factors, such as age and disease severity, to better predict patient outcomes.
Directions for Future Acute Liver Failure Research
A 2023 review frames acute liver failure as rapid hepatocyte injury that leads to coagulopathy and encephalopathy in the absence of pre-existing cirrhosis. It identifies prolonged prothrombin time, expressed as an elevated international normalized ratio, among the hallmark diagnostic features. The supplied excerpt does not specify future interventions or research priorities. It therefore supports the clinical framework for future work, but not a particular forecast about steroid treatment.
While steroids might have a role in certain liver conditions, this study urges caution when considering their use in hepatitis B-related ACLF. Further research is needed to explore alternative treatments and preventive strategies that can improve survival rates and quality of life for these patients.
If you or a loved one is dealing with ACLF, it's crucial to discuss these findings with your healthcare provider. Together, you can explore the most appropriate treatment options, taking into account individual risk factors and the latest evidence-based guidelines.